Vivek Subbiah, MD, discusses how the data from selpercatinib have generated excitement for precision medicine in the treatment landscape for patients with RET-driven lung cancer.
Vivek Subbiah, MD, of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the data from selpercatinib have generated excitement for precision medicine in the treatment landscape for patients with RET-driven lung cancer.
The LIBRETTO-001 study demonstrated promising activity with selpercatinib, the selective RET inhibitor, as treatment of patients with RET-mutant non-small cell lung cancer (NSCLC). Subbiah says that this study generated the enthusiasm in precision oncology for RET-driven NSCLC.
This opens up new areas of precision oncology, as well as the opportunity for precision medicine in patients with RET-driven NSCLC. Approval of this agent furthers the use of selpercatinib in the community setting, Subbiah notes. This now demonstrates proof of principal for selective RET inhibition, so we need to know when patients will receive the most benefit from specific RET targeting, which is upfront, in Subbiah’s personal opinion.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More